Johnson & Johnson, getting ready for a consumer spinoff next year, has big plans in pharma over the next decade.
Within 3 years (2025), the company seeks to generate $60 billion in pharma sales, leaning generally on existing medications for growth till then. New Top Dog Joaquin Duato stated during the virtual J.P. Morgan Healthcare Conference today (10th January 2022). Between 2025-2030, this company expects a small number of new launches to contribute in a major way.
Among the health care giant’s pipeline, Duato highlighted five plans that could create $5 billion or even more in top sales. Those usually are the Legend Biotech-partnered CAR-T medicine Carvykti, the potential “pipeline within a product” medication Nipocalimab, Rybrevant in lung cancer, a new potential first-in-class oral Factor XIa inhibitor Milvexian and also a possible bladder cancer system called Taris.
Carvykti is a “best-in-class” BCMA CAR-T medication for multiple myeloma that could alter the “paradigm of treatment” through possible combinations, Duato mentioned. Carvykti is expected to launch later this year after the Food and Drug Administration (FDA) postponed its approval decision in November.
Meanwhile, Rybrevant won an FDA approval last year to treat adults with non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations. In combination with Yuhan Corp.’s Leclaza, the drug could transform treatment for certain patients with lung cancer, J&J said during the November business review.
Duato highlighted the promising candidates during a one-on-one conversation with J.P. Morgan senior analyst Chris Schott. After taking the reins last week, the CEO said he’ll continue to manage the healthcare giant as a “three-sector company” as J&J preps for its consumer healthcare spinoff late next year. Within the pharma business, J&J expects big-sellers such as cancer drug Darzalex and immunology med Tremfya to chip in most of the growth through the decade’s halfway point.
To reach its $60 billion goal for the pharma unit, the company is planning to file 36 applications for new indications, new line expansions or new formulations for 13 existing blockbuster products by 2025, Duato said. Those medicines will drive the majority of J&J’s growth through 2025, the CEO added.
J&J is checking on the extension to offset predicted sales declines to get megablockbuster immunology medicine Stelara, which seems to lose U.S. obvious protections next calendar year. The drug generated $6.8 billion during the first nine months of 2021 and is currently J&J’s largest product by sales.